Mino-Lok recently received Fast Track designation by the FDA
Citius
Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care and
critical care drug products, has announced that clinical trial supplies
of Mino-Lok (minocycline/edetate/ethanol) have been sent to the University of Chicago Medical Center, and the Henry Ford Health System in Detroit,
the first 2 clinical trial sites for the Mino-Lok phase 3 pivotal
trial. When fully recruited, it is planned that there will be 50
participating sites, all located in the U.S.
Mr. Myron Holubiak, Chief Executive Officer of Citius, commented, "We have reached a key milestone in advancing this innovative product to an NDA. Mino-Lok clinical trial supplies have been sent to two of the most prestigious institutions in the US in preparation for the initiation of our phase 3 pivotal trial. We have discussed the urgent need to find an alternative to CVC removal as an approach to treating Catheter Related Blood Stream Infections (CRBSIs). We are very excited to finally begin our pivotal trial. We believe that the worldwide market potential for Mino-Lok exceeds $1 billion."
There are currently no approved therapies to salvage infected central venous catheters. CRBSIs are responsible for mortality rates of up to 25% in some patients, and contribute to significant morbidities.
Mino-Lok™ is under investigation and not approved for commercial use.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.
No comments:
Post a Comment